Copyright © 2006, European Society of Cardiology
Biology of atherosclerotic plaques: What we are learning from proteomic analysis
aVascular Research Laboratory, Fundación Jiménez Díaz, Avenida Reyes Católicos 2, 28040, Madrid, Spain
bINSERM Unit 698, Cardiovascular Hematology, Bio-Engineering and Remodeling, CHU X-Bichat, Université Paris 7, Paris, France
cDepartment of Immunology, Fundación Jiménez Díaz, Autonoma University, Madrid, Spain
* Corresponding author. Tel.: +34 91 5504800x3362; fax: +34 91 5442636. Email address: jegido{at}fjd.es
Atherosclerotic plaque rupture triggers the onset of cardiovascular complications such as myocardial infarction and stroke, which represent the main cause of death in western countries. Atherogenesis is a complex process characterized by lipid retention, proteolytic injury and a chronic inflammatory response. The resulting pathological vascular remodeling involves inflammatory cell recruitment, fibrosis, smooth muscle cell proliferation, neovascularization and intraplaque hemorrhage. However, the cellular and molecular mechanisms underlying cardiovascular dysfunction remain widely unknown. The development of differential proteomics allows the identification of novel proteins whose association with the genesis of atherosclerotic plaques is at present unforeseen in the light of available data. Moreover, different strategies have been used to discover new potential biomarkers which could be related to cardiovascular risk. The multi-factorial nature of cardiovascular diseases necessitates the use of biomarkers for early detection, for monitoring the response to therapy and to predict clinical outcome. In this review, we summarize the different proteomic approaches and recent findings that will help us to understand the mechanisms implicated in the pathogenesis of atherothrombosis.
KEYWORDS Proteomics; Atherosclerosis
1 The first two authors contributed equally to this work.
Time for primary review 51 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C Lopez-Pedrera, N Barbarroja, M. Aguirre, L. Torres, F Velasco, and M. Cuadrado Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases Lupus, October 1, 2008; 17(10): 905 - 916. [Abstract] [PDF]
|
|
|
|
 |
|
 A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Levi and E. Stroes Targeting the prevention of plaque rupture as a new strategy for prevention of acute arterial cardiovascular events Cardiovasc Res, June 1, 2008; 78(3): 407 - 408. [Full Text] [PDF]
|
|
|
|
|
|
B. Martinson, M. P. Hans, G.-D. David, and A. M. Elizabeth Readers' choice: Hot papers downloaded in 2006 Cardiovasc Res, March 1, 2007; 73(4): 619 - 622. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Matt, T. Carrel, M. White, I. Lefkovits, and J. Van Eyk Proteomics in cardiovascular surgery J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 210 - 214. [Abstract] [Full Text] [PDF]
|
|